Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02272946 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 23, 2014
Last Update Posted : November 10, 2021
|
Sponsor:
Priscilla Hsue, MD
Information provided by (Responsible Party):
Priscilla Hsue, MD, University of California, San Francisco
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | February 2021 |
| Estimated Study Completion Date : | December 2022 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
September 1, 2022 | September 30, 2022 |
| 2 |
October 12, 2022 | November 4, 2022 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):